{"id":17397,"date":"2025-05-24T13:00:26","date_gmt":"2025-05-24T11:00:26","guid":{"rendered":"https:\/\/www.ifpma.org\/?post_type=news&p=17397"},"modified":"2025-05-26T09:40:22","modified_gmt":"2025-05-26T07:40:22","slug":"ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases","status":"publish","type":"news","link":"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/","title":{"rendered":"IFPMA welcomes the adoption of the WHA78 Resolution on rare diseases"},"content":{"rendered":"

On 24 May 2025, a resolution on rare diseases was adopted at the 78th session of the World Health Assembly. IFPMA issued a statement in support of the resolution.<\/p>\n

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), together with its member companies and associations, welcomes the adoption of the World Health Assembly (WHA) Resolution on Rare Diseases.<\/p>\n

This Resolution marks a pivotal step in accelerating action for rare diseases. With over 300 million people living with a rare disease (PLWRD) globally\u2014and many more undiagnosed\u2014this initiative reflects a growing commitment to address the unmet needs of this diverse and underserved community.<\/p>\n

We commend the leadership of Egypt and Spain, along with the 27 co-sponsoring Member States, for their commitment to advancing this Resolution. We also laud the efforts of the Rare Diseases International Coalition, which has brought together 275 stakeholders in support of the Resolution and Global Action Plan. as well as the coalition of civil society organizations led by Rare Diseases International.<\/p>\n

The proposed Global Action Plan on Rare Diseases (GAPRD), as called for by the Resolution, represents a unique opportunity to develop coordinated and sustainable approaches that improve early diagnosis, care pathways, and health innovation.<\/p>\n

We strongly support an inclusive, consultative process for the development of the GAPRD\u2014one that involves people living with rare diseases, caregivers and families, patient organizations, healthcare providers, governments, and industry. Such a plan can inspire and guide national and regional strategies to improve early diagnosis, care, and treatment\u2014while also fostering innovation for unmet medical needs.<\/p>\n

As the innovative pharmaceutical industry, we reaffirm our commitment to partnering across sectors to drive forward research and development in rare diseases, while supporting access to care and treatment solutions that reflect local realities.<\/p>\n

We look forward to continuing our collaboration with the World Health Organization, Member States, and all stakeholders to turn the vision of this Resolution into tangible outcomes that improve lives worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"

On 24 May 2025, a resolution on rare diseases was adopted at the 78th session of the World Health Assembly. IFPMA issued a statement in support of the resolution. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), together with its member companies and associations, welcomes the adoption of the World Health Assembly (WHA) Resolution…<\/p>\n","protected":false},"featured_media":0,"template":"","news_type":[4],"topic":[17],"class_list":["post-17397","news","type-news","status-publish","hentry","news_type-statement","topic-rare-diseases"],"acf":[],"yoast_head":"\nIFPMA welcomes the adoption of the WHA78 Resolution on rare diseases | IFPMA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IFPMA welcomes the adoption of the WHA78 Resolution on rare diseases | IFPMA\" \/>\n<meta property=\"og:description\" content=\"On 24 May 2025, a resolution on rare diseases was adopted at the 78th session of the World Health Assembly. IFPMA issued a statement in support of the resolution. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), together with its member companies and associations, welcomes the adoption of the World Health Assembly (WHA) Resolution...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"IFPMA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IFPMA\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-26T07:40:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-social-preview.png\" \/>\n\t<meta property=\"og:image:width\" content=\"801\" \/>\n\t<meta property=\"og:image:height\" content=\"801\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@IFPMA\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/\",\"url\":\"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/\",\"name\":\"IFPMA welcomes the adoption of the WHA78 Resolution on rare diseases | IFPMA\",\"isPartOf\":{\"@id\":\"https:\/\/www.ifpma.org\/#website\"},\"datePublished\":\"2025-05-24T11:00:26+00:00\",\"dateModified\":\"2025-05-26T07:40:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ifpma.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/www.ifpma.org\/news\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IFPMA welcomes the adoption of the WHA78 Resolution on rare diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ifpma.org\/#website\",\"url\":\"https:\/\/www.ifpma.org\/\",\"name\":\"IFPMA\",\"description\":\"Innovating to improve health worldwide\",\"publisher\":{\"@id\":\"https:\/\/www.ifpma.org\/#organization\"},\"alternateName\":\"International Federation of Pharmaceutical Manufacturers and Associations\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ifpma.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ifpma.org\/#organization\",\"name\":\"IFPMA\",\"alternateName\":\"International Federation of Pharmaceutical Manufacturers and Associations\",\"url\":\"https:\/\/www.ifpma.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png\",\"contentUrl\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png\",\"width\":1379,\"height\":733,\"caption\":\"IFPMA\"},\"image\":{\"@id\":\"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/IFPMA\/\",\"https:\/\/x.com\/IFPMA\",\"https:\/\/www.linkedin.com\/company\/ifpma\/\",\"https:\/\/www.youtube.com\/user\/ifpma\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IFPMA welcomes the adoption of the WHA78 Resolution on rare diseases | IFPMA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/","og_locale":"en_US","og_type":"article","og_title":"IFPMA welcomes the adoption of the WHA78 Resolution on rare diseases | IFPMA","og_description":"On 24 May 2025, a resolution on rare diseases was adopted at the 78th session of the World Health Assembly. IFPMA issued a statement in support of the resolution. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), together with its member companies and associations, welcomes the adoption of the World Health Assembly (WHA) Resolution...","og_url":"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/","og_site_name":"IFPMA","article_publisher":"https:\/\/www.facebook.com\/IFPMA\/","article_modified_time":"2025-05-26T07:40:22+00:00","og_image":[{"width":801,"height":801,"url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-social-preview.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@IFPMA","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/","url":"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/","name":"IFPMA welcomes the adoption of the WHA78 Resolution on rare diseases | IFPMA","isPartOf":{"@id":"https:\/\/www.ifpma.org\/#website"},"datePublished":"2025-05-24T11:00:26+00:00","dateModified":"2025-05-26T07:40:22+00:00","breadcrumb":{"@id":"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ifpma.org\/news\/ifpma-welcomes-the-adoption-of-the-wha78-resolution-on-rare-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ifpma.org\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.ifpma.org\/news\/"},{"@type":"ListItem","position":3,"name":"IFPMA welcomes the adoption of the WHA78 Resolution on rare diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.ifpma.org\/#website","url":"https:\/\/www.ifpma.org\/","name":"IFPMA","description":"Innovating to improve health worldwide","publisher":{"@id":"https:\/\/www.ifpma.org\/#organization"},"alternateName":"International Federation of Pharmaceutical Manufacturers and Associations","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ifpma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ifpma.org\/#organization","name":"IFPMA","alternateName":"International Federation of Pharmaceutical Manufacturers and Associations","url":"https:\/\/www.ifpma.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png","contentUrl":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png","width":1379,"height":733,"caption":"IFPMA"},"image":{"@id":"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/IFPMA\/","https:\/\/x.com\/IFPMA","https:\/\/www.linkedin.com\/company\/ifpma\/","https:\/\/www.youtube.com\/user\/ifpma"]}]}},"_links":{"self":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/news\/17397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/media?parent=17397"}],"wp:term":[{"taxonomy":"news_type","embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/news_type?post=17397"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/topic?post=17397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}